A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter in endometrial carcinomas

被引:79
作者
Nishioka, Y
Kobayashi, K
Sagae, S
Ishioka, S
Nishikawa, A
Matsushima, M
Kanamori, Y
Minaguchi, T
Nakamura, Y
Tokino, T
Kudo, R
机构
[1] Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Obstet & Gynecol,Chuo Ku, Sapporo, Hokkaido 0600061, Japan
[2] Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Mol Biol,Chuo Ku, Sapporo, Hokkaido 0600061, Japan
[3] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan
来源
JAPANESE JOURNAL OF CANCER RESEARCH | 2000年 / 91卷 / 06期
关键词
matrix metalloproteinase-1; single nucleotide polymorphism; human endometrial carcinoma;
D O I
10.1111/j.1349-7006.2000.tb00989.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent studies demonstrated that a single guanine insertion polymorphism in a matrix metallopretease-1 promoter created an Ets binding site and affected the elevation of the transcriptional level of matrix metalloproteinase-1 (MMP-1). Furthermore, in tumor cell lines derived from melanoma and breast cancer, the incidence of the 2G/2G genotype was significantly higher than that in the normal population, To evaluate the contribution of this polymorphism in endometrial carcinomas, we genotyped 100 endometrial carcinomas and then analyzed immunoexpression of MMP-1 in these carcinomas. We found that endometrial carcinoma patients showed a significantly higher rate of 1G/2G or 2G/2G genotype than control individuals, and that tumors containing the 2G allele(a) expressed MMP-1 protein more frequently than those,vith 1G/1G genotype. Therefore, the single nucleotide polymorphism at the MMP-1 promoter affected the expression level of the MMP-1 protein, which may result in the association with more aggressive character in endometrial carcinoma. Our result suggests that the presence of 2G polymorphism at the, MMP-1 promoter may be one of the risk factors for the development and/or progression of endometrial carcinoma.
引用
收藏
页码:612 / 615
页数:4
相关论文
共 14 条
[1]  
ABELER VM, 1991, CANCER, V67, P3093, DOI 10.1002/1097-0142(19910615)67:12<3093::AID-CNCR2820671226>3.0.CO
[2]  
2-L
[3]  
*AM CANC SOC, 1995, CANC FACTS FIG 1995
[4]   Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases [J].
Borden, P ;
Heller, RA .
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 1997, 7 (1-2) :159-178
[5]  
*FIGO STAG, 1989, GYNECOL ONCOL
[6]   BIOLOGY OF TUMOR-METASTASIS [J].
HART, IR ;
SAINI, A .
LANCET, 1992, 339 (8807) :1453-1457
[7]  
Kanamori Y, 1999, CANCER RES, V59, P4225
[8]  
KOHN EC, 1995, CANCER RES, V55, P1856
[9]   Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer [J].
Murray, GI ;
Duncan, ME ;
ONeil, P ;
Melvin, WT ;
Fothergill, JE .
NATURE MEDICINE, 1996, 2 (04) :461-462
[10]  
Murray GI, 1998, J PATHOL, V185, P256